Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12771037rdf:typepubmed:Citationlld:pubmed
pubmed-article:12771037lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C0000545lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C0015689lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C0596244lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12771037lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:12771037pubmed:issue5lld:pubmed
pubmed-article:12771037pubmed:dateCreated2003-5-28lld:pubmed
pubmed-article:12771037pubmed:abstractTextDietary omega-3 polyunsaturated fatty acids (omega-3 PUFAs) protect against photocarcinogenesis in animals, but prospective human studies are scarce. The mechanism(s) underlying the photoprotection are uncertain, although omega-3 PUFAs may influence oxidative stress. We examined the effect of supplementation on a range of indicators of ultraviolet radiation (UVR)-induced DNA damage in humans, and assessed effect on basal and post-UVR oxidative status. In a double-blind randomized study, 42 healthy subjects took 4 g daily of purified omega-3 PUFA, eicosapentaenoic acid (EPA), or monounsaturated, oleic acid (OA), for 3 months. EPA was bioavailable; the skin content at 3 months showing an 8-fold rise from baseline, P < 0.01. No consistent pattern of alteration in basal and UVR-exposed skin content of the antioxidants glutathione, vitamins E and C or lipid peroxidation, was seen on supplementation. Sunburn sensitivity was reduced on EPA, the UVR-induced erythemal threshold rising from a mean of 36 (SD 10) mJ/cm(2) at baseline to 49 (16) mJ/cm(2) after supplementation, P < 0.01. Moreover, UVR-induced skin p53 expression, assessed immunohistochemically at 24 h post-UVR exposure, fell from a mean of 16 (SD 5) positive cells/100 epidermal cells at baseline to 8 (4) after EPA supplementation, P < 0.01. Peripheral blood lymphocytes (PBL) sampled on 3 successive days both pre- and post-supplementation, showed no change with respect to basal DNA single-strand breaks or oxidative base modification (8-oxo-dG). However, when susceptibility of PBL to ex vivo UVR was examined using the comet assay, this revealed a reduction in tail moment from 84.4 (SD 3.4) at baseline to 69.4 (3.1) after EPA, P = 0.03. No significant changes were seen in any of the above parameters following OA supplementation. Reduction in this range of early markers, i.e. sunburn, UVR-induced p53 in skin and strand breaks in PBL, indicate protection by dietary EPA against acute UVR-induced genotoxicity; longer-term supplementation might reduce skin cancer in humans.lld:pubmed
pubmed-article:12771037pubmed:languageenglld:pubmed
pubmed-article:12771037pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:citationSubsetIMlld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12771037pubmed:statusMEDLINElld:pubmed
pubmed-article:12771037pubmed:monthMaylld:pubmed
pubmed-article:12771037pubmed:issn0143-3334lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:McArdleFFlld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:MoisonRalf...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:Beijersbergen...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:EpeBerndBlld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:VinkArie AAAlld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:ShahbakhtiHas...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:RhodesLesley...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:AzurdiaRichar...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:SteenwinkelMa...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:HomburgMarie...lld:pubmed
pubmed-article:12771037pubmed:authorpubmed-author:DeanMichael...lld:pubmed
pubmed-article:12771037pubmed:issnTypePrintlld:pubmed
pubmed-article:12771037pubmed:volume24lld:pubmed
pubmed-article:12771037pubmed:ownerNLMlld:pubmed
pubmed-article:12771037pubmed:authorsCompleteYlld:pubmed
pubmed-article:12771037pubmed:pagination919-25lld:pubmed
pubmed-article:12771037pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:meshHeadingpubmed-meshheading:12771037...lld:pubmed
pubmed-article:12771037pubmed:year2003lld:pubmed
pubmed-article:12771037pubmed:articleTitleEffect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers.lld:pubmed
pubmed-article:12771037pubmed:affiliationPhotobiology Unit, Dermatology Centre, University of Manchester, UK. lesley.e.rhodes@man.ac.uklld:pubmed
pubmed-article:12771037pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12771037pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12771037pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12771037pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12771037pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12771037lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12771037lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12771037lld:pubmed